ESG Overview

ESG Overview

Since our founding, we have understood that by operating in a sustainable manner, benefits accrue to our employees, investors, environment, communities, and the patients we seek to serve. Ultimately, patients are at the center of our corporate citizenship efforts, and all else at Reata. We are stewards of novel compounds with the potential to increase quality of life and life expectancy. Today, our lead programs are in rare, life-threatening diseases for which there are no approved therapies currently available.

Our work to bring forward innovative medicines for areas of severe unmet need is, at its core, a driver of positive social impact. Bardoxolone methyl and omaveloxolone have the potential to become the first therapies specifically indicated to slow the progression of disease in patients with CKD caused by Alport syndrome and in patients with Friedreich’s ataxia, respectively. At Reata, we strive to be a leader in the way we incorporate a patient focus across functions.

ESG Pillars

Hamilton Pool